Abstract
Summary
Patients with chronic hepatitis C have low bone mineral density and increased bone resorption related to serum transaminase levels. Elevated serum soluble tumor necrosis factor (sTNFR-55) receptor levels may play a role in the bone mass loss in these patients. Bone mass is improved and bone turnover normalized in patients who respond to antiviral therapy with interferon and ribavirin.
Introduction
Low bone mineral density (BMD) has been described in patients with chronic hepatitis C (HCV). The study objective was to evaluate the effect of antiviral therapy on BMD and bone metabolism in non-cirrhotic HCV patients with sustained virological response.
Methods
We conducted a prospective study in 36 consecutive outpatients from the general community with non-cirrhotic HCV and an early and sustained virological response to peginterferon-alfa and ribavirin therapy. Determinations of BMD (dual X-ray absorptiometry at lumbar spine and femoral neck) and biochemical measurements of bone metabolism and sTNFR-55 were made at baseline, after 24 and 48 weeks of antiviral therapy, and at 48 weeks after the end of treatment.
Results
Patients had a significantly reduced BMD, which significantly increased during the follow-up. Serum levels of sTNFR-55 and bone turnover markers were increased at baseline and significantly reduced at all subsequent time points. We found an inverse correlation between BMD and both serum aminotransferase levels and urine deoxypyridinoline (D-pyr) and a positive correlation between serum aminotransferases and both urine D-Pyr and serum sTNFR-55.
Conclusions
Patients with chronic hepatitis C have low bone mass associated with increased bone resorption, and some relationship can be expected between serum aminotransferase levels and the degree of bone mass loss. Bone mass may be improved and bone turnover normalized in patients who respond to antiviral therapy. Elevated serum sTRFR-55 levels may play a role in the bone mass loss of these patients.
Similar content being viewed by others
References
Collier JD, Ninkovic M, Compston J (2002) Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50:i1–i9
Leslie WD, Bernstein CN, Leboff MS (2003) American Gastroenterological Association Clinical Practice Committee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125:941–966
Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D (1998) Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28:695–699
Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J (1997) Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148–154
Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG (2004) Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 89:4325–4330
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518
Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD (1989) Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 4:113–118
Van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Löwik C (1991) Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 129:1596–1604
Kull FC Jr (1988) The TNF receptor in TNF-mediated cytotoxicity. Nat Immun Cell Growth Regul 7:254–265
Peetre C, Thysell H, Grubb A, Olsson I (1988) A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 41:414–419
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329
Diez-Ruiz A, Tilz GP, Gutierrez-Gea F, Gil-Extremera B, Murr C, Wachter H, Fuchs D (1995) Neopterin and soluble tumor necrosis factor receptor type I in alcohol-induced cirrhosis. Hepatology 21:976–978
González-Calvin JL, Tilz GP, Gallego-Rojo F, Torres-Almendros M, Widner B, Diez-Ruiz A, Rico-Irles J, Fuchs D (2000) Neopterin, soluble receptors for interleukin-2 and tumor necrosis factor in viral cirrhosis. Pteridines 11:43–47
Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11:1843–1847
Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bücker A, Mihm U, von Wagner M, Zeuzem S, Sarrazin C (2008) Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 15:790–796
Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, Chu HC (2012) Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int 91:423–429
Solís-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F (2000) Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 33:812–817
Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37:600–609
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994) Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520
Hytiroglou P, Thung SN, Gerber MA (1995) Histological classification and quantitation of the severity of chronic hepatitis: keep it simple. Semin Liver Dis 15:414–421
Diaz Curiel M, Carrasco de la Peña JL, Honorato Perez J, Perez Cano R, Rapado A, Ruiz Martinez I (1997) Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. Multicentre Research Project on Osteoporosis. Osteoporos Int 7:59–64
Who Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Tech Rep Ser 843. World Health Organization, Geneva
Parfitt AM (1980) Morphologic basis of bone mineral measurement: transient and steady-state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273–287
El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS, Brown TT (2011) Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 55:770–776
Gur A, Dikici B, Nas K, Bosnak M, Haspolat K, Sarac AJ (2005) Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol 5:30
Wilkison M, Gauss K, Ran Y, Searles S, Taylor D, Meissner N (2012) Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection. Am J Pathol 181:151–162
Moreira RO, Balduíno A, Martins HS, Reis JS, Duarte ME, Farias ML, Borojevic R (2004) Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 75:160–168
Trombetti A, Giostra E, Mentha G, Negro F, Rizzoli R (2002) Lack of evidence for ribavirin-induced bone loss. Hepatology 36:255–257
Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R (1993) Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 8:881–889
Eriksen EF, Brixen K, Charles P (1995) New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 132:251–263
Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453–1463
Bikle DD, Genant HK, Cann C, Recker RR, Halloran BP, Strewler GJ (1985) Bone disease in alcohol abuse. Ann Intern Med 103:42–48
Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S (1989) Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96:213–221
Acknowledgments
We thank Jorge González Cantero, medical student at the University of Granada, for technical assistance. This work was supported by a Grant from Consejería de Salud, Junta de Andalucía (PI-0134/2007) and from the University of Granada (Beca de Iniciación a la Investigación del Plan Propio 2011).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Redondo-Cerezo, E., Casado-Caballero, F., Martin-Rodriguez, J.L. et al. Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin. Osteoporos Int 25, 1709–1715 (2014). https://doi.org/10.1007/s00198-014-2663-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2663-z